PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsamyloidosis
MeSH D000686 - amyloidosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D057165:Proteostasis deficiencies
0 Companies
0 Drugs
Success rate
D000686: 
Amyloidosis
41 Companies
6 Drugs
$
Success rate
D000075363:Immunoglobulin light-chain amyloidosis
0 Companies
0 Drugs
Success rate
D016657:Cerebral amyloid angiopathy
0 Companies
0 Drugs
Success rate
D017772:Amyloid neuropathies
0 Companies
0 Drugs
Success rate
D028226:Familial amyloidosis
1 Company
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
PfizerTafamidis Vyndaqel  2011-11-16 $3,321 M Y2023 
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
83%
19/23
Phase 2
36%
10/28
Phase 3
26%
5/19
Approved: 4Overall Success rate: 8%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Merck Sharp & Dohme
Colchicine
Pfizer
Tafamidis,
Tafamidis meglumine
Takeda
Colchicine
Arbor Pharmaceuticals
Acetylcysteine
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use